The sodium glucose cotransporter 2 inhibitor ipragliflozin promotes preferential loss of fat mass in non-obese diabetic Goto-Kakizaki rats

Biological and Pharmaceutical Bulletin

Volumn 40, Issue 5, 2017, Pages 675-680

  Takasu, Toshiyuki ^a   Hayashizaki, Yuka ^a   Hirosumi, Jiro ^a   Minoura, Hideaki ^a   Amino, Nobuaki ^a   Kurosaki, Eiji ^a   Takakura, Shoji ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Anti diabetic drug; Body composition; Ipragliflozin; Sodium glucose cotransporter 2 (SGLT2) inhibitor; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; IPRAGLIFLOZIN; ANTIDIABETIC AGENT; GLUCOSIDE; SGLT2 PROTEIN, RAT; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BONE MINERAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EVENING DOSAGE; FAT MASS; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HEMOGLOBIN BLOOD LEVEL; INSULIN BLOOD LEVEL; LEAN BODY WEIGHT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; WEIGHT GAIN; ADIPOSE TISSUE; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY WEIGHT LOSS; DRUG EFFECTS; EATING; GLUCOSURIA; LIPID DIET; METABOLISM; PATHOLOGY; PHOTON ABSORPTIOMETRY; WISTAR RAT;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ANIMALS; BODY COMPOSITION; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; EATING; GLUCOSIDES; GLYCOSURIA; HYPOGLYCEMIC AGENTS; MALE; RATS; RATS, WISTAR; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; WEIGHT LOSS;

EID: 85019201035     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b16-00964     Document Type: Article

References (40)

1. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care, 29, 1130-1139 (2006).
2. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia, 53, 1270-1287 (2010).
3. Palermo A, Maggi D, Maurizi AR, Pozzilli P, Buzzetti R. Prevention of type 2 diabetes mellitus: is it feasible? Diabetes Metab. Res. Rev., 30 (Suppl. 1), 4-12 (2014).
4. Sattar N, Gill JM. Type 2 diabetes as a disease of ectopic fat? BMC Med., 12, 123 (2014).
5. Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW, Smith RJ, Smith SR, Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care, 34, 1424-1430 (2011).
6. Aguilar RB. Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success. Clin. Ther., 33, 408-424 (2011).
7. Pi-Sunyer FX. Weight loss in type 2 diabetic patients. Diabetes Care, 28, 1526-1527 (2005).
8. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr. Rev., 32, 515-531 (2011).
9. Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism, 63, 1228-1237 (2014).
10. Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther., 1, 57-92 (2010).
11. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu. Rev. Med., 66, 255-270 (2015).
12. Rajeev SP, Cuthbertson DJ, Wilding JP. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes Obes. Metab., 18, 125-134 (2016).
13. Kashiwagi A, Kazuta K, Yoshida S, Nagase I. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J. Diabetes Investig., 5, 382-391 (2014).
14. Kashiwagi A, Kazuta K, Goto K, Yoshida S, Ueyama E, Utsuno A. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes Obes. Metab., 17, 304-308 (2015).
15. Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes: Interim outcome of the ASSIGN-K study. J. Clin. Med. Res., 8, 116-125 (2016).
16. Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity, 20, 1645-1652 (2012).
17. Yokono M, Takasu T, Hayashizaki Y, Mitsuoka K, Kihara R, Muramatsu Y, Miyoshi S, Tahara A, Kurosaki E, Li Q, Tomiyama H, Sasamata M, Shibasaki M, Uchiyama Y. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur. J. Pharmacol., 727, 66-74 (2014).
18. Suzuki M, Takeda M, Kito A, Fukazawa M, Yata T, Yamamoto M, Nagata T, Fukuzawa T, Yamane M, Honda K, Suzuki Y, Kawabe Y. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutrition & Diabetes, 4, e125 (2014).
19. Goto Y, Kakizaki M, Masaki N. Production of spontaneous diabetic rats by repetition of selective breeding. Tohoku J. Exp. Med., 119, 85-90 (1976).
20. Bisbis S, Bailbe D, Tormo MA, Picarel-Blanchot F, Derouet M, Simon J, Portha B. Insulin resistance in the GK rat: decreased receptor number but normal kinase activity in liver. Am. J. Physiol., 265, E807-E813 (1993).
21. O'Rourke CM, Davis JA, Saltiel AR, Cornicelli JA. Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus. Metabolism, 46, 192-198 (1997).
22. Ueta K, Ishihara T, Matsumoto Y, Oku A, Nawano M, Fujita T, Saito A, Arakawa K. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci., 76, 2655-2668 (2005).
23. Movassat J, Bailbe D, Lubrano-Berthelier C, Picarel-Blanchot F, Bertin E, Mourot J, Portha B. Follow-up of GK rats during prediabetes highlights increased insulin action and fat deposition despite low insulin secretion. Am. J. Physiol. Endocrinol. Metab., 294, E168-E175 (2008).
24. Portha B, Lacraz G, Kergoat M, Homo-Delarche F, Giroix MH, Bailbe D, Gangnerau MN, Dolz M, Tourrel-Cuzin C, Movassat J. The GK rat beta-cell: a prototype for the diseased human beta-cell in type 2 diabetes? Mol. Cell. Endocrinol., 297, 73-85 (2009).
25. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Qun L, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedeberg's Arch. Pharmacol., 385, 423-436 (2012).
26. Takasu T, Hayashizaki Y, Tahara A, Kurosaki E, Takakura S. Antihyperglycemic effect of ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, in combination with oral antidiabetic drugs in mice. Clin. Exp. Pharmacol. Physiol., 42, 87-93 (2015).
27. Veltkamp SA, van Dijk J, Collins C, van Bruijnsvoort M, Kadokura T, Smulders RA. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clin. Ther., 34, 1761-1771 (2012).
28. Fonseca VA, Ferrannini E, Wilding JP, Wilpshaar W, Dhanjal P, Ball G, Klasen S. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J. Diabetes Complications, 27, 268-273 (2013).
29. Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes. Metab., 15, 403-409 (2013).
30. Engelbregt MJ, van Weissenbruch MM, Popp-Snijders C, Lips P, Delemarre-van de Waal HA. Body mass index, body composition, and leptin at onset of puberty in male and female rats after intrauterine growth retardation and after early postnatal food restriction. Pediatr. Res., 50, 474-478 (2001).
31. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur. J. Pharmacol., 715, 246-255 (2013).
32. Millar PJ, Pathak V, Moffett RC, Pathak NM, Bjourson AJ, O'Kane MJ, Flatt PR, Gault VA. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice. Mol. Cell. Endocrinol., 420, 37-45 (2016).
33. Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, Du F, Liu Y, Xu J, Conway B, Conway J, Polidori D, Ways K, Demarest K. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS ONE, 7, e30555 (2012).
34. Vickers SP, Cheetham SC, Headland KR, Dickinson K, Grempler R, Mayoux E, Mark M, Klein T. Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes Metab. Syndr. Obes. Target Ther., 7, 265-275 (2014).
35. Pouliot MC, Despres JP, Nadeau A, Moorjani S, Prud'Homme D, Lupien PJ, Tremblay A, Bouchard C. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes, 41, 826-834 (1992).
36. Bu J, Feng Q, Ran J, Li Q, Mei G, Zhang Y. Visceral fat mass is always, but adipokines (adiponectin and resistin) are diversely associated with insulin resistance in Chinese type 2 diabetic and normoglycemic subjects. Diabetes Res. Clin. Pract., 96, 163-169 (2012).
37. Taniguchi A, Nakai Y, Sakai M, Yoshii S, Hamanaka D, Hatae Y, Kawata M, Yamanouchi K, Okumura T, Doi K, Tokuyama K, Nagasaka S, Fukushima M. Relationship of regional adiposity to insulin resistance and serum triglyceride levels in nonobese Japanese type 2 diabetic patients. Metabolism, 51, 544-548 (2002).
38. Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J. Clin. Endocrinol. Metab., 97, 1020-1031 (2012).
39. Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, Sugg J, Parikh S. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes. Metab., 16, 159-169 (2014).
40. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, Xiong J, Perez Z, Norton L, Abdul-Ghani MA, DeFronzo RA. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest., 124, 509-514 (2014).